Schonfeld Strategic Advisors LLC Makes New Investment in Electromed, Inc. (NYSE:ELMD)

Schonfeld Strategic Advisors LLC bought a new position in shares of Electromed, Inc. (NYSE:ELMD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,996 shares of the company's stock, valued at approximately $768,000. Schonfeld Strategic Advisors LLC owned about 0.30% of Electromed as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership grew its position in shares of Electromed by 261.0% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company's stock valued at $3,386,000 after purchasing an additional 82,839 shares during the last quarter. Northern Trust Corp increased its position in Electromed by 14.1% during the 4th quarter. Northern Trust Corp now owns 65,350 shares of the company's stock worth $1,931,000 after buying an additional 8,086 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Electromed during the fourth quarter worth $1,760,000. Susquehanna International Group LLP boosted its position in shares of Electromed by 121.8% in the fourth quarter. Susquehanna International Group LLP now owns 56,726 shares of the company's stock valued at $1,676,000 after acquiring an additional 31,148 shares during the period. Finally, Navellier & Associates Inc. grew its stake in shares of Electromed by 228.5% in the fourth quarter. Navellier & Associates Inc. now owns 56,368 shares of the company's stock valued at $1,666,000 after acquiring an additional 39,208 shares in the last quarter. 40.82% of the stock is owned by institutional investors.

Insider Activity

In other Electromed news, Director Andrew Summers sold 50,751 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.30, for a total transaction of $1,385,502.30. Following the completion of the transaction, the director now directly owns 65,714 shares in the company, valued at $1,793,992.20. The trade was a 43.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kathleen Skarvan sold 8,640 shares of the firm's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $32.25, for a total value of $278,640.00. Following the completion of the sale, the director now directly owns 71,576 shares in the company, valued at approximately $2,308,326. This represents a 10.77 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 133,618 shares of company stock worth $3,821,636. 14.00% of the stock is currently owned by corporate insiders.

Electromed Stock Performance

Shares of NYSE ELMD traded down $0.03 during mid-day trading on Friday, reaching $22.20. The company had a trading volume of 41,638 shares, compared to its average volume of 69,491. Electromed, Inc. has a one year low of $13.74 and a one year high of $35.56. The business's 50-day simple moving average is $23.51 and its 200 day simple moving average is $27.38. The firm has a market cap of $189.97 million, a price-to-earnings ratio of 29.60 and a beta of 0.46.

Electromed declared that its board has approved a share repurchase program on Monday, March 10th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company's management believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have issued reports on ELMD shares. StockNews.com downgraded shares of Electromed from a "strong-buy" rating to a "buy" rating in a report on Thursday. B. Riley assumed coverage on Electromed in a research note on Thursday, February 20th. They issued a "buy" rating and a $38.00 price target for the company.

About Electromed

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.